Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Products under Development by Stage of Development | 8 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Products under Development by Therapy Area | 9 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Products under Development by Indication | 10 | 2 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Products under Development by Companies | 14 | 3 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Companies Involved in Therapeutics Development | 23 | 4 |
| Anthera Pharmaceuticals Inc. | 23 | 1 |
| Eli Lilly and Company | 24 | 1 |
| GlaxoSmithKline Plc | 25 | 1 |
| Merck KGaA | 26 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Drug Profiles | 27 | 21 |
| atacicept Drug Profile | 27 | 2 |
| belimumab Drug Profile | 29 | 6 |
| blisibimod Drug Profile | 35 | 7 |
| BLyS-gel Drug Profile | 42 | 1 |
| Monoclonal Antibodies to Inhibit BAFF for B-Cell Lymphoma Drug Profile | 43 | 1 |
| Monoclonal Antibody to Inhibit BAFF and IL-17 for Immunology Drug Profile | 44 | 1 |
| OSX-100 Drug Profile | 45 | 1 |
| OSX-110 Drug Profile | 46 | 1 |
| RCT-18 Drug Profile | 47 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Dormant Projects | 48 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Discontinued Products | 49 | 1 |
| Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Featured News &Press Releases | 50 | 13 |
| Jun 28, 2016: Anthera Provides Clinical Program Update for Blisibimod | 50 | 1 |
| Jun 08, 2016: New Phase III data shows greater treatment response with GSK s Benlysta (belimumab) vs placebo in patients with highly active SLE | 51 | 2 |
| Mar 03, 2016: New long-term organ damage analysis published for GSK s Benlysta (belimumab) | 53 | 1 |
| Nov 07, 2015: GSK announces positive results from phase III BLISS-SC study of Benlysta (belimumab) administered subcutaneously in patients with systemic lupus erythematosus | 54 | 1 |
| Jun 16, 2015: Anthera Pharmaceuticals Has Reached Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod | 55 | 1 |
| Jun 04, 2015: Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study | 56 | 1 |
| Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy | 56 | 1 |
| Feb 10, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus | 56 | 1 |
| Dec 30, 2014: Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference | 57 | 1 |
| Oct 01, 2014: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod | 58 | 1 |
| Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting | 58 | 1 |
| Jul 23, 2013: NICE consults on belimumab for systemic lupus erythematosus | 59 | 1 |
| Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod | 60 | 1 |
| May 07, 2013: Anthera Pharma Announces Additional Data From Phase IIb PEARL-SC Blisibimod Study | 60 | 1 |
| Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis | 61 | 2 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |